Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Comparison of Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopy (MRS) as Bioenergetic Imaging Modalities in Healthy Human Brain and Major Depressive Disorder

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01465165

Enrollment

Registered

2011-11-04

Start date

2011-05-15

Completion date

2012-06-24

Last updated

2017-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Depression, Positron emission tomography, Magnetic resonance spectroscopy, glucose metabolism, ATP, phosphocreatine

Brief summary

Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders. The current study utilizes two distinct but complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and multinuclear magnetic resonance spectroscopy (MRS), to better understand the nature of these metabolic abnormalities in major depressive disorder (MDD). The investigators hypothesize that individuals with depression will have increased metabolic activity as measured by PET in certain brain regions involved in mood regulation, but that this metabolic activity will be inefficient based on MRS findings. For this study, the investigators will study 10 medication-free, currently depressed participants with recurrent MDD, 10 depressed participants with recurrent MDD currently taking antidepressant medication, and up to 20 healthy control participants matched to depressed participants for age and gender. Depressed and healthy participants will each undergo one PET scan and one MRS scanning session.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Meet DSM-IV criteria for Major Depressive Disorder (MDD), Recurrent * Montgomery-Asberg Depression Rating Scale (MADRS) score \> 18

Exclusion criteria

* Any coexisting psychiatric illness other than generalized anxiety disorder, panic disorder, or social/specific phobias * Any history of substance dependence * Substance abuse within the past 6 months * Significant risk of suicide, as defined by score \>4 on item 10 of the MADRS or in the clinical judgment of the study physician * Any significant medical or neurological condition which is likely to impact the central nervous system and/or affect the results of MRS or PET imaging * For the subset of unmedicated MDD patients, any psychotropic medications within 4 weeks prior to scanning. For the subgroup of medicated patients, they may be taking a stable dose (i.e., same dose for at least 4 weeks at the time of scanning) of standard antidepressant medications, but may not be taking any other psychotropic medication. * Inability to give informed consent * Contraindication to MRI (e.g., pacemaker, ferromagnetic implants in the body)

Design outcomes

Primary

Measure	Time frame	Description
high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy	cross-sectional	relative concentration of Pcr

Secondary

Measure	Time frame	Description
regional cerebral glucose metabolism, as measured by Positron Emission Tomography (PET)	cross-sectional	binding potential of FDG
N-Acetyl-Aspartate (NAA) metabolite intensity, as measured by proton Magnetic Resonance Spectroscopy (MRS)	cross-sectional	relative concentration of NAA
severity of depressive symptoms, as scored on the Montgomery-Asberg Depression Rating Scale (MADRS)	cross-sectional	MADRS composite score

Countries

United States

Outcome results